Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the ...
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
Machine learning-powered drug discoverer Recursion Pharmaceuticals has secured $121 million in new financing for its artificial intelligence programs. The proceeds will help the former Fierce 15 ...
MarketBeat on MSN
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?
CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback